BCR and cancer: Numerous technologies, including fluorescence in-situ hybridization (for karyotypic characterization), comparative genomic hybridization (CGH, for small chromosomal rearrangements and copy number variation), and recently next generation whole genome sequencing, allow the detailed characterization of chromosomal abnormalities predisposing to cancer development, and the identification cancer cell-specific alterations that help explain the abnormal cell growth or resistance to treatment, as in the case of the formation of fusion genes such as BCR-ABL (Philadelphia Chromosome) [28].